Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

Dow Jones

04/10

1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 07:45 ET (11:45 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2626192182"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2626192182\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2626192182?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626192182","market":"sg","top_or_hot":-1,"title":"Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:45 ET (11:45 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 19:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:45 ET (11:45 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211331839.USD","symbol_name":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626192182","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626192182","pubTimestamp":1775821500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","NVS":"诺华","BK4578":"CAR-T","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4588":"碎股","ISBC":"投资者银行","BK4007":"制药","BK4211":"区域性银行","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"诺华投资者在业绩疲软的情况下将重点关注产品线更新——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"ISBC":1.5},"content_text":"1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 07:45 ET (11:45 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}